Summarized by Masters of Longevity from Singularity Hub.
Researchers dosed the first patient with a liver-targeted prime editor this month.
Key Takeaways
- A prime editor was infused into a Wilson disease patient.
- Animal tests showed liver edits with no notable short-term harms.
- Clinical safety and efficacy have not been established yet.
